Accuvance works closely with a premier clinical-stage regenerative medicine company addressing conditions and diseases affecting sporting and domestic animals globally for which current treatments are ineffective, not fully effective, or palliative. They have developed allogeneic equine cord blood stem cells as well as canine adipose-derived mesenchymal stromal cells to provide novel therapeutic options.
Our Cell Series include banked allogeneic cells and autologous cell services. The company has access to other cell types, such as canine pluripotent stem cells, and can custom procure cells to meet individual needs for domestic animal cells.
